D. Boral Capital Reaffirms Buy Rating for Medicus Pharma (NASDAQ:MDCX)

Medicus Pharma (NASDAQ:MDCX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $27.00 price target on the stock.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Medicus Pharma in a research note on Monday, December 8th. Zacks Research upgraded Medicus Pharma to a “hold” rating in a report on Monday, September 15th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.50.

Medicus Pharma Stock Performance

Shares of Medicus Pharma stock opened at $1.80 on Monday. Medicus Pharma has a 52-week low of $1.68 and a 52-week high of $8.94. The company’s 50 day moving average price is $2.22 and its 200-day moving average price is $2.44. The stock has a market capitalization of $39.65 million and a price-to-earnings ratio of -0.84.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.27). As a group, equities research analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Institutional Trading of Medicus Pharma

A number of hedge funds have recently modified their holdings of the business. Armistice Capital LLC bought a new stake in Medicus Pharma during the first quarter worth about $4,710,000. SeaCrest Wealth Management LLC purchased a new position in shares of Medicus Pharma during the second quarter valued at approximately $139,000. Guyasuta Investment Advisors Inc. bought a new stake in shares of Medicus Pharma in the 2nd quarter worth approximately $230,000. May Hill Capital LLC purchased a new stake in shares of Medicus Pharma in the 2nd quarter worth approximately $107,000. Finally, Jane Street Group LLC purchased a new stake in shares of Medicus Pharma in the 2nd quarter worth approximately $41,000.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.